INTRODUCTION
A number of publications in the last few years widely support the concept that there are two major populations of lymphocytes, one derived from thymus (T cells)' and the other from bone marrow (B cells) (1) . To identify these two populations cell markers such as surfacebound immunoglobulin (2) (3) (4) , receptor for third component of complement (C3 receptor) (5, 6) , receptor for Fc fragment of IgG (Fc receptor) (7, 8) , and membrane antigens (9-11) have been used, however, the reliability of some of these markers has recently come into question (12) (13) (14) (15) . Antigenic analysis is potentially useful for these purposes since it may be possible to detect a variety of surface components rather than single molecular types such as surface Ig. Distinct surface antigens have been demonstrated in lymphocyte populations by a variety of sensitive serological techniques such as cytotoxicity, immunofluorescence, immunoferritin, and mixed agglutination. In mice, for example, specific antigenic markers have been distinguished on the surface membranes of both T and B lymphocytes by either alloor hetero-antisera (9-11, 16, 17) . Thymus-specific antigens have also been detected on rabbit T cells (18) . In man, the recognition of antigenic determinants specifically associated with either T-or B-lymphocyte populations has met with only partial success (19, 20) . It appears that antisera raised against fetal thymus (21) , ' Abbreviations used in this paper: B cells, bone marrowderived lymphocytes; C3 receptor, receptor for third component of complement; CRL, complement receptor lymphocyte; CLL, chronic lymphatic leukemia; E, sheep erythrocyte; EAC, erythrocyte-IgM antibody-complement complexes; ERFC, sheep erythrocyte rosette-forming cells; Fc receptor, receptor for Fc fragment of IgG; FCS, fetal calf serum; NHS, normal human serum; RhaNS, rhesus antinormal spleen antiserum; RhaBCL, rhesus antilymphoblastoid B-cell line antiserum; RhaCLL, rhesus antichronic lymphatic leukemia antiserum; T cells, thymus-derived lymphocytes.
The Journal of Clinical Investigation Volume 57 February 1976.390-397emulsified cerebrum (22) , and peripheral lymphocytes from agammaglobulinemic patients (23) retain some degree of T-cell specificity after absorption with chronic lymphatic leukemia lymphocytes (CLL) and lymphoblastoid cultured cells. Also, certain B-cellassociated activity has been detected in antisera raised against CLL cells and absorbed with thymus (24) . However, it has been found difficult to standardize and make reproducible the production of such antisera. As a result of HL-A typing and antigenic studies on leukemia cells, quantitative and qualitative antigenic differences have been found between normal and leukemia lymphocytes. These differences have been defined as the absence of normal determinants or the existence of extra antigens on the surface of leukemic cells, not found on normal peripheral lymphocytes (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) . Similarly, heterogeneity in surface antigens have also been observed in normal human lymphocytes under long-term culture conditions (35) (36) . Thus it is of interest to define further the antigenic heterogeneity of CLL cells and cultured lymphoid cells.
The present study was undertaken to characterize further the cell-surface antigens present on normal human lymphocytes, lymphocytes from patients with CLL and lymphoblastoid B cells, using antisera raised in primates.
METHODS Clinical material, cell separation. Peripheral blood lymphocytes from normal subjects, cord blood, blood from patients with chronic and acute lymphatic leukemia and agammaglobulinemia were separated by using a procedure combining sequentially, phagocytic loading with carbonyl iron particles, sedimentation in dextran, and centrifugation on Hypaque-Ficoll. Blood was collected in heparinized syringes (2-5 U/ml) and then mixed with 1%o poly-L-lysinesensitized carbonyl iron suspension in Hank's balanced salt solution (HBSS) prewarmed to 370C containing twice the regular amount of CaCl, and MgCl2 and 3% T250 dextran, placed in a horizontal axial rotator, and rotated at 15 rpm at 370C for 50 min. Erythrocytes and cells with ingested iron were then sedimented at room temperature for 60-90 min. Finally, the leukocyte-rich supernate was diluted with 2 vol of saline, and each 20 ml was layered onto 5 ml of Hypaque-Ficoll (d 1.077 g/ml) in siliconized 23 X 105-mm glass centrifuge tubes and centrifuged at 4°C, 500 g, for 20 min. Cells from the interface were harvested. This preparation contained 91-97%o lymphocytes which were over 95% viable and represented 50-70% of the original blood lymphocyte population. Cells were washed three times in HBSS (without Ca++ and Mg++) or saline before use. CLL blood was only processed with dextran sedimentation and Hypaque-Ficoll since the leukocyte population contained more than 90%o lymphocytes. The recovery obtained with CLL cells was at least 70%o of the starting lymphoid population.
Cultured human lymphoid cells. Cultured lymphoblastoid cell lines were established at the Veterans Administration Hospital, Denver, from the buffy coat of six different normal blood donors. They are designated as shown in the tables, according to the initials of the donors from whom they were established. The cells were maintained in spinner culture at a concentration of 1-5 X 106/ml of RPMI 1640 containing 10% fetal calf serum (FCS), 2 mM glutamine, 100 ,ug streptomycin/ml, and 100 U penicillin/ml for long periods of time (months). Cultured cells for absorption and testing were obtained from the spinner flasks at the time of harvesting (biweekly) and washed in 40-50 vol of cold saline three times before use.
Antilymphocyte sera. Rhesus monkeys were immunized with human lymphocytes (normal spleen, cultured lymphoblastoid cells, and peripheral blood lymphocytes from one patient with CLL) by injecting 1-3 X 108 washed cells intramuscularly in complete Freund's adjuvant every 2 wk for a variable period of time (2-10 mo). Immunizing cells were always obtained from the same source, either by periodic sampling or by using cells stored in liquid nitrogen. Serum samples were collected at different stages of immunization and stored at -700C.
Heat inactivated (560C, 30 min) undiluted antisera from one or more bleeding samples were used for absorption. Even though none of the antilymphocyte sera showed detectable activity against normal human serum (NHS) by immunodiffusion, all were absorbed with 100 mg of lyophilized whole NHS/ml. The antisera had some activity against human erythrocytes when tested by hemagglutination. One or two absorptions with one-fifth serum volume of packed AB-RH-positive erythrocyte stroma were necessary to absorb out all of the agglutinin activity. Absorption with cells were performed under constant mixing by using a horizontal axial rotator at 40 rpm, first for 1 h at room temperature and then 8-10 h at 40 C. Human liver was used as a source of nonlymphoid absorbing cells. The viability of the cells used for absorption was in general over 80%. The absorption procedure did not result in any major change in protein concentration in the antisera, as measured by nephelometry. The final absorptions involved varying amount of human lymphoid cells as detailed in Results. Cytotoxicity assay. The antilymphocyte sera were assayed by cytotoxicity using both the dye uptake and 'Crrelease method. A slight modification of Wigzell's method of 'Cr labeling was used (37) . This consisted of labeling lymphocytes resuspended in 200 ul of 5% FCS Tris buffer pH 7.2. The use of a reduced number of cells (5-10 X 10') in a smaller volume results in higher specific cell labeling and allows the use of only 1-4 X 104 target cells per assay. Equal volumes (50 ul) of cells, antisera in serial dilutions, and undiluted normal rabbit serum (absorbed with 5 X 106 human leukocytes/ml) as the source of complement, were incubated for 1 h at 37°C. After incubation with medium, complement or antiserum the mean spontaneous isotope release was 14% (SD = 2.8). Maximum variation in the 'Cr release within duplicate or triplicate tests did not represent more than 2.7% of the total 'Cr release (mean = 1.25; SD = 0.8). Specific 'Cr release was estimated using the following formula: (Counts released with antiserumcounts released with normal serum)/(counts released with freeze thawed cells -counts released with normal serum or maximum counts released with antiserum) X 100.
The dilution of an antiserum required for 50% 'Cr release was used as an end point. When the dye exclusion method was used, the assay was set up similarly and either 0.1% trypan blue or 0.5%7 eosin was used for microscope visualization.
Immunofluorescence. The antilymphocyte sera were also tested by indirect immunofluorescence using rabbit antirhesus gamma globulin conjugated with fluorescein isothiocyanate. Antiserum to rhesus gamma globulin was produced in rabbits which were rendered tolerant to human gamma globulin by injecting intravenously ultracentrifuged Cohn II fraction of human serum according to a method previously described (38) . Although the rabbit anti-rhesus gamma globulin showed no cross-reactivity with human strum proteins by immunodiffusion, its IgG fraction was absorbed on a human gamma globulin-conjugated Sepharose 4B column. After this, the immunoabsorbed serum was fluoresceinated as described elsewhere (3) (39, 42) . When B cells from one cell line (Bj) were used to absorb RhaNS, 0.6 X 10' cells/ml of serum were needed for an effective absorption. The effectiveness of the absorption was monitored by the loss of both cytotoxic reactivity and indirect immunofluorescent staining of absorbing cells. However, after this absorption, activity was still detected against 100% of normal peripheral lymphocytes, CLL cells, and other cultured B cells (Table I). Therefore no indication of selective T-cell killing was detected with this absorbed antiserum. In contrast to those results the same antiserum, RhaNS, when absorbed with a pool of five different cultured B cells, showed no reactivity against any cultured B cells or CLL cells tested (Table II) . However, between 65-80% of the normal peripheral blood lymphocytes and 46% of a tonsil cell preparation were killed by the absorbed antiserum. Evidence that this partial killing was not due to the weakness of the antiserum was obtained by the dose-response experiment shown in Fig. 1 . A clear plateau of activity against a proportion of lymphoid cells was obtained using the absorbed antiserum up to 1: 9 dilution, suggesting that this antiserum was selectively killing a subpopulation of normal lymphocytes. In Table   II (Table V) . RhaBCL. This antiserum against leukemic cells was produced in a rhesus monkey (RhaCLL) by injecting peripheral blood lymphocytes from CLL patient (Me), over 90% of which bore B-cell markers. The cytotoxic titers of RhaCLL ranged between 1: 350 and 1: 8,000 against leukemic lymphocytes, and had a mean of 1: 1,600 against normal lymphocytes. To determine whether this antiserum could discriminate leukemic cells from normal lymphocytes, experiments were performed to study the reactivity of RhaCLL after absorption with normal lymphocytes. Several absorptions with 3.4 X 10' tonsil cells/ml of serum, were needed to remove all of the cytotoxic reactivity against normal lymphocytes. The absorbing cells represented a pool obtained from 10 individuals and possessed most of the common HL-A antigens. Table IV shows that 75-80% of the leukemic cells from two CLL patients tested were still killed by the absorbed antiserum, whereas the absorbed antiserum had no effect on the normal or cultured B lymphocytes reacted. These results indicate that RhaCLL absorbed with tonsil is able to recognize differences between CLL and normal lymphocytes. A second approach was used to study further the specificity of RhaCLL. RhaCLL was absorbed with 2.4 X 10' peripheral blood lymphocytes/ml of serum from another CLL patient (Ste). This absorption effectively removed cytotoxic activity against eight normal lymphocyte samples, cells from three malignant lymphoproliferative disorders, three cultured lymphoblastoid cell lines, and two cord blood lymphocyte samples (Table V) . However, activity remained against 12 CLL preparations. This activity was not related to the HL-A system, since normal cells with similar HL-A profiles to some of the CLL cells tested did not react. Further absorptions with cells from another CLL patient (Cia) were carried out on RhaCLL. This antiserum revealed obvious heterogeneity among CLL cells, since this antiserum still reacted with 4 of 12 CLL tested. The possibility was considered that some of the activity in these absorbed antisera was due to anti-IgM or anti-IgD antibodies, since the immunizing cells were known to carry these Ig classes. Although no antibody with such specificity was detected by immunodiffusion, soluble absorptions were carried out with purified IgM and IgD myeloma proteins. No loss of cytotoxic activity was observed after these absorptions.
Immunofluorescence. Simultaneous studies were performed with rhesus antilymphocyte sera by cytotoxicity and by immunofluorescence. When an antiserum which showed 100% cytotoxic reactivity was tested by immunofluorescence, 100% of the cells were strongly stained. Similarly, if an absorbed antiserum with no cytotoxic activity against the absorbing cells was assayed by fluorescence, faint or negative staining was seen. However, when an antiserum such as RhaNS (Table II) which showed partial cytotoxic activity against a given population of cells (65-80% normal peripheral blood) was studied, no correlation could be found with the extent of fluorescent staining since a higher proportion of cells were stained. Similar findings were seen in comparable studies done on CLL cells with RhaCLL absorbed with Ste cells (Table V) . DISCUSSION Although there are numerous communications describing specific antimouse T-and B-cell antisera, there have been only a few studies reporting similar reagents for human In our studies we chose rhesus monkeys as responding animals, in the expectation that they would offer the best possibility of producing antibodies directed against minor antigenic differences that might be present on human lymphocyte subpopulations. Indeed some evidence was obtained from our experiments that rhesus anti-CLL serum contained antibodies specifically reactive with minor determinants, against which similarly prepared rabbit antisera had no activity. For instance, the detection of C3d receptors (borne by the immunizing cells) was specifically inhibited by the rhesus antiserum and not by the rabbit antiserum (42) . Furthermore, rhesus antispleen serum had inhibitory activity against both C3b and C3d receptors (present on splenocytes), whereas analogous antisera raised in rabbits did not.
To analyze our antisera we used the cytotoxicity and immunofluorescence techniques, both of which have been shown to be sensitive and reliable for studying cellmembrane antigens. In comparative studies we found that cell populations which showed either 100 or 0% reactivity with antisera, did so by both methods. However, using cells among which a subpopulation reacted, there was no strict correlation between the population of cells killed and the proportion showing fluorescent staining. A higher proportion of fluorescent-stained cells was seen. This discrepancy can be explained by the differences in the sensitivity of the methods used, by the nature of the antibodies (some antibodies not complement fixing), or by the binding of Ig molecules to cell membranes other than through the Fab region (i.e., Fc receptor). This disagreement has already been postulated by other authors (41) .
In our attempts to obtain an antiserum specific for human T cells, RhaNS was absorbed with five lymphoblastoid cell lines. After absorption, the antiserum showed reactivity for a subpopulation of normal lymphocytes constituting 60-75% of peripheral blood lymphoid cells. The proportion of cells with which the serum reacted correlated well with the proportion of ERFC detected in the same preparation. However, when cells were tested for ERFC after cytotoxicity treatment, a significant proportion of viable ERFC remained. The facts that the antiserum had no inhibitory activity against the formation of E rosettes, and nonviable cells failed to form E rosettes (39) made this combined assay a reliable test. We conclude, therefore, that this absorbed antiserum had cytotoxic activity against a subset of ERFC which represent approximately 75-95% of the peripheral T-cell population. Since the proportion of lymphocytes killed by the antiserum cannot be attributed entirely to the ERFC population, it can be concluded that the serum was also active against a small subpopulation of non-ERFC. These studies suggest antigenic heterogeneity within the T-cell population detected by the E-rosette assay and furthermore suggest the presence of shared antigens between ERFC and a subpopulation of non-ERFC.
Other evidence of antigenic heterogeneity was obtained from studies of CLL-cell and B-cell lines. Cultured lymphoblastoid cells carry membrane receptors present on normal B cells, and it has been thought that their antigenic mosaic may be close to that on normal B lymphocytes, For this reason B-cell lines have been used as absorbents in the preparation of specific anti-T sera. Our findings indicate that such cultured cells are antigenically distinguishable from normal cells, and apparently lack some normal B-cell antigens. Moreover, they show antigenic heterogeneity, as demonstrated by our studies with RhaNS and RhaBCL. It is not possible to assess at this point, whether this heterogeneity is unique to the B-cell line or whether it represents antigenic heterogeneity also present on small subpopulations of normal B lymphocytes.
We confirm previous reports (33) of the ability of monkeys to raise antibodies against antigens associated with CLL cells and not detectable on normal cells (Table IV). CLL cells from different patients showed variable reactivity with the antisera. After absorptions with cells from the two most reactive patients (Table V) , we found that the differences in cell reactivity were probably due to a major antigenic heterogeneity of CLL cells. The nature of these CLL-associated antigens is difficult to define. They may represent antigens associated with an expanded subpopulation of normal lymphocytes which are present but not detectable by means of our techniques. This argument follows to some extent the rationalization applied to the antigenic definition of myeloma proteins. However, the alternate possibility remains that these are true leukemia-associated determinants, which themselves might reflect dedifferentiation or other intrinsic changes specifically associated with the neoplastic process, such as the appearance of virus induced neo-antigens. Further studies of these leukemiaantigens and of the antigenic heterogeneity of cells from different lymphoproliferative diseases, may provide useful insights into lymphocyte antigenic structure.
